{"brief_title": "Trial to Reduce Cardiovascular Events With Aranesp\u00ae Therapy (TREAT)", "brief_summary": "The purpose of this study is to assess the impact of treatment of anemia with darbepoetin alfa to a hemoglobin target of 13 g/dL on (1) all-cause mortality and nonfatal cardiovascular events, and (2) progression to end-stage renal disease or death, in subjects with chronic kidney disease and type 2 diabetes mellitus. Academic PI/Executive Committee Chairman: Marc Pfeffer, MD, PhD", "condition": ["Kidney Disease", "Diabetes Mellitus", "Anemia"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["Placebo", "darbepoetin alfa"], "description": ["Volume and dose frequency changes resembling dosing in the active treatment group", "Starting dose : 0.75 mcg/kg subcutaneous (SC) every two weeks (Q2W); subsequent doses titrated to achieve hemoglobin (Hb) target of 13.0 g/dL"], "arm_group_label": ["Placebo", "Active"], "criteria": "Inclusion Criteria: - Hemoglobin less than or equal to 11 g/dL - History of Chronic Kidney Disease - eGFR (estimated glomerular filtration rate) greater than or equal to 20 mL/min/1.73 m2 and less than or equal to 60 mL/min/1.73 m2 - Tsat (transferrin saturation) greater than 15% Exclusion Criteria: - Uncontrolled hypertension - Erythropoietic protein use within 12 weeks of randomization", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Diabetes Mellitus", "Kidney Diseases", "Darbepoetin alfa"], "id": "NCT00093015"}